Developer docs
API playgroundTry for free, no card

Search company profiles

Livsmed

Full company profile

uuid0006kxv

Namestring
Livsmed
Legal namestring
Livsmed Inc.
Websiteurl
livsmed.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Livsmed Inc. is a Korean medical device company founded in 2011 and listed on the KOSDAQ exchange (ticker 491000) since December 2025, headquartered in South Korea with a San Diego presence and 101–250 employees. The company designs and manufactures surgical instruments for minimally invasive procedures, anchored by the ArtiSential handheld laparoscopic device, a multi-joint, multi-degrees-of-freedom articulating instrument that gives surgeons greater dexterity than conventional rigid laparoscopic tools. Livsmed is transitioning from a single-product handheld instrument maker into a robotic surgery platform company, anchored by STARK, which the company positions as the world's first telesurgery-native robotic surgical system, featuring 90° articulation and a smaller footprint than incumbent robotic platforms.

The core technology is the multi-joint, multi-DOF surgical instrument platform, protected by an IP portfolio of 939 items (including 63 patents, 17 trademarks, and 9 designs acquired from U.S.-based FlexDex Surgical in January 2026 as a blocking patent strategy). STARK's telesurgery capability was demonstrated across 2,000 miles (Santa Barbara, CA to Chicago, IL) in partnership with Sovato, with surgeons from City of Hope completing cholecystectomy, gastrojejunostomy, and partial liver resection on a porcine model. The company earns revenue through hardware sales of ArtiSential instruments and STARK robotic systems to hospitals and healthcare systems via an enterprise field sales motion.

The business model is capital-intensive medical device hardware sales with no disclosed pricing; the December 2025 KOSDAQ IPO raised approximately $94 million at ₩55,000 per share, achieving unicorn status with roughly $1 billion market capitalization. Proceeds are allocated to an integrated production base, R&D, and management systems to support global expansion. The investor base includes Stonebridge Ventures (12.72% pre-secondary, now reduced), major domestic Korean pension funds, institutions, and global financial firms. Founder-tier leadership is not disclosed in available source material.

Short descriptiontext

Livsmed is a Korean medical device company that designs and sells minimally invasive surgical instruments, including the ArtiSential handheld articulating laparoscopic device and the STARK telesurgery-native robotic system, serving hospitals and healthcare systems globally.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
surgical robotics, laparoscopic instruments, minimally invasive surgery, telesurgery systems, medical device manufacturing
Industry2 codes
1Surgical Robotics & Computer-Assisted Surgery Platforms
CodeHLAHADAFPrimaryYes
2Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
CodeHLAHADAAPrimaryNo
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Robotics and Minimally Invasive Surgical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Surgical Instruments and Robotics Hardware
TypeHardware Sales
Description

LivsMed generates revenue from the sale of handheld laparoscopic surgical devices (ArtiSential) and robotic surgical systems (STARK) to hospitals and healthcare providers.

openpr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ArtiSential
Description

Laparoscopic surgical device developed by Livsmed

biz.chosun.com
+2 more records
Core offering1 text field

Livsmed manufactures and sells minimally invasive surgical hardware, including the ArtiSential multi-joint handheld laparoscopic surgical device and the STARK telesurgery-native robotic surgical system. Products are sold to hospitals and healthcare providers for use in laparoscopic and robotic minimally invasive surgical procedures, including long-distance telesurgery applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Livsmed is a Korean medical device company offering a portfolio of surgical instruments spanning handheld laparoscopic devices and robotic surgery systems. The company's core products include the ArtiSential laparoscopic surgical device and the STARK telesurgery-native robotic surgical system. Livsmed has expanded its IP portfolio to 939 items through organic development and acquisition of FlexDex assets (89 IP rights including 63 patents, 17 trademarks, and 9 designs), covering the entire multi-joint, multi-degrees-of-freedom surgical instrument platform. The company transitioned from a KOSDAQ listing in December 2025 and completed an IPO raising approximately $94 million, achieving unicorn status with a market capitalization of roughly $1 billion.

Product and service2 records
1ArtiSential
CategoryLaparoscopic Surgical Instruments
Description

Multi-joint, multi-degrees-of-freedom handheld laparoscopic surgical device used by surgeons in hospitals and healthcare systems for minimally invasive procedures.

2STARK Surgical Robot
CategorySurgical Robotics Systems
Description

World's first telesurgery-native robotic surgical system designed to make advanced remote robotic surgery affordable and accessible globally. Features 90-degree articulation and a smaller footprint than existing robotic systems, enabling long-distance telesurgery.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-12
Description

Livsmed acquired technology assets including 89 intellectual property rights (63 patents, 17 trademarks, 9 designs) from U.S. surgical instrument specialist FlexDex Surgical. The acquisition covers the entire multi-joint, multi-degrees-of-freedom surgical instrument platform, serving as a blocking patent strategy against rivals.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-14
Description

LivsMed partnered with Sovato to remote-enable the STARK surgical robot platform. The companies successfully demonstrated long-distance telesurgery across 2,000 miles (Santa Barbara, CA to Chicago, IL) using the STARK platform. Sovato provides the remote-enabling technology component for the telesurgery-native robotic surgical system.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of the da Vinci surgical robot, the dominant platform in robotic-assisted minimally invasive surgery. Most directly comparable to Livsmed's STARK robotic system and a benchmark competitor for hospital procurement.

TypeDirect peer
Description

Develops the Hugo robotic-assisted surgery system targeting the same laparoscopic surgical robotics market as STARK. Competes for hospital capital budgets and articulating instrument IP.

TypeDirect peer
Description

Developing the Ottava robotic surgery platform and a broad laparoscopic instrument portfolio. Overlaps with Livsmed's ArtiSential handheld devices and STARK robotic system across hospitals.

TypeEmerging player
Description

Early-stage surgical robotics company developing a smaller-footprint robotic-assisted laparoscopic platform (Maestro). Competes on the same cost-and-footprint value proposition as STARK.

TypeEmerging player
Description

Develops a single-port robotic surgical system with virtual reality and decoupled actuator architecture. Targets abdominal minimally invasive surgery, overlapping with Livsmed's articulating instrument approach.

TypeDirect peer
Description

Maker of the Versius surgical robot, a modular, small-footprint robotic system competing in laparoscopic procedures. Most directly comparable to STARK on cost/accessibility positioning outside the US.

TypeBroad incumbent
Description

Operates the Mako robotic surgery platform (orthopedics) plus a broad surgical instruments and endoscopy portfolio. A broad incumbent with overlapping surgical robotics ambitions.

TypeBroad incumbent
Description

Global leader in endoscopic and laparoscopic instruments with recent robotics investments (including Asensus Surgical). Directly comparable product portfolio in laparoscopic visualization and instrumentation.

TypeBroad incumbent
Description

Major laparoscopic/endoscopic instrument manufacturer with growing surgical robotics exposure. Competes with Livsmed's ArtiSential in articulating laparoscopic instruments and adjacent to STARK.

TypeEmerging player
Description

U.S. surgical instrument specialist whose IP assets (89 items) were acquired by Livsmed. Originally developed articulating needle drivers/instruments in the same multi-joint category as ArtiSential.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Livsmed

Surgical Robotics and Minimally Invasive Surgical Deviceslivsmed.com

Livsmed is a Korean medical device company that designs and sells minimally invasive surgical instruments, including the ArtiSential handheld articulating laparoscopic device and the STARK telesurgery-native robotic system, serving hospitals and healthcare systems globally.

What Livsmed does

Livsmed Inc. is a Korean medical device company founded in 2011 and listed on the KOSDAQ exchange (ticker 491000) since December 2025, headquartered in South Korea with a San Diego presence and 101–250 employees. The company designs and manufactures surgical instruments for minimally invasive procedures, anchored by the ArtiSential handheld laparoscopic device, a multi-joint, multi-degrees-of-freedom articulating instrument that gives surgeons greater dexterity than conventional rigid laparoscopic tools. Livsmed is transitioning from a single-product handheld instrument maker into a robotic surgery platform company, anchored by STARK, which the company positions as the world's first telesurgery-native robotic surgical system, featuring 90° articulation and a smaller footprint than incumbent robotic platforms.

The core technology is the multi-joint, multi-DOF surgical instrument platform, protected by an IP portfolio of 939 items (including 63 patents, 17 trademarks, and 9 designs acquired from U.S.-based FlexDex Surgical in January 2026 as a blocking patent strategy). STARK's telesurgery capability was demonstrated across 2,000 miles (Santa Barbara, CA to Chicago, IL) in partnership with Sovato, with surgeons from City of Hope completing cholecystectomy, gastrojejunostomy, and partial liver resection on a porcine model. The company earns revenue through hardware sales of ArtiSential instruments and STARK robotic systems to hospitals and healthcare systems via an enterprise field sales motion.

The business model is capital-intensive medical device hardware sales with no disclosed pricing; the December 2025 KOSDAQ IPO raised approximately $94 million at ₩55,000 per share, achieving unicorn status with roughly $1 billion market capitalization. Proceeds are allocated to an integrated production base, R&D, and management systems to support global expansion. The investor base includes Stonebridge Ventures (12.72% pre-secondary, now reduced), major domestic Korean pension funds, institutions, and global financial firms. Founder-tier leadership is not disclosed in available source material.

Livsmed firmographics

Firmographics
Name
Livsmed
Legal name
Livsmed Inc.
Website
https://livsmed.com
Company type
Public
Founded year
2015
Operating status
Ipo
Headcount range
101–250 employees
Short description
Livsmed is a Korean medical device company that designs and sells minimally invasive surgical instruments, including the ArtiSential handheld articulating laparoscopic device and the STARK telesurgery-native robotic system, serving hospitals and healthcare systems globally.
Ownership category
akta.pro rank

Livsmed industry classification

Industry
Product category
Surgical Robotics and Minimally Invasive Surgical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
akta.pro secondary industry
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

  • Surgical robotics
  • Laparoscopic instruments
  • Minimally invasive surgery
  • Telesurgery systems
  • Medical device manufacturing

Where Livsmed is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Livsmed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

  1. Surgical Instruments and Robotics Hardware: LivsMed generates revenue from the sale of handheld laparoscopic surgical devices (ArtiSential) and robotic surgical systems (STARK) to hospitals and healthcare providers.

Go-to-market motion1 record

Marketing channels1 record

Livsmed product offering

Product offering

Core offering

Livsmed manufactures and sells minimally invasive surgical hardware, including the ArtiSential multi-joint handheld laparoscopic surgical device and the STARK telesurgery-native robotic surgical system. Products are sold to hospitals and healthcare providers for use in laparoscopic and robotic minimally invasive surgical procedures, including long-distance telesurgery applications.

Product overview

Livsmed is a Korean medical device company offering a portfolio of surgical instruments spanning handheld laparoscopic devices and robotic surgery systems. The company's core products include the ArtiSential laparoscopic surgical device and the STARK telesurgery-native robotic surgical system. Livsmed has expanded its IP portfolio to 939 items through organic development and acquisition of FlexDex assets (89 IP rights including 63 patents, 17 trademarks, and 9 designs), covering the entire multi-joint, multi-degrees-of-freedom surgical instrument platform. The company transitioned from a KOSDAQ listing in December 2025 and completed an IPO raising approximately $94 million, achieving unicorn status with a market capitalization of roughly $1 billion.

Differentiator

Problem solved

Functional benefit

Brands

  • ArtiSential: Laparoscopic surgical device developed by Livsmed
  • STARK
  • STARK Surgical Robot

Products and services

  • ArtiSential Multi-joint, multi-degrees-of-freedom handheld laparoscopic surgical device used by surgeons in hospitals and healthcare systems for minimally invasive procedures.
  • STARK Surgical Robot World's first telesurgery-native robotic surgical system designed to make advanced remote robotic surgery affordable and accessible globally. Features 90-degree articulation and a smaller footprint than existing robotic systems, enabling long-distance telesurgery.

Companies that use Livsmed

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Livsmed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Livsmed partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • FlexDex SurgicalcoreTechnology or Integration · 12 January 2026Livsmed acquired technology assets including 89 intellectual property rights (63 patents, 17 trademarks, 9 designs) from U.S. surgical instrument specialist FlexDex Surgical. The acquisition covers the entire multi-joint, multi-degrees-of-freedom surgical instrument platform, serving as a blocking patent strategy against rivals.
  • SovatocoreTechnology or Integration · 14 July 2025LivsMed partnered with Sovato to remote-enable the STARK surgical robot platform. The companies successfully demonstrated long-distance telesurgery across 2,000 miles (Santa Barbara, CA to Chicago, IL) using the STARK platform. Sovato provides the remote-enabling technology component for the telesurgery-native robotic surgical system.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Livsmed competitors and assessment

Company assessment

Direct peers

  • Intuitive Surgical: Maker of the da Vinci surgical robot, the dominant platform in robotic-assisted minimally invasive surgery. Most directly comparable to Livsmed's STARK robotic system and a benchmark competitor for hospital procurement.
  • Medtronic: Develops the Hugo robotic-assisted surgery system targeting the same laparoscopic surgical robotics market as STARK. Competes for hospital capital budgets and articulating instrument IP.
  • Johnson & Johnson MedTech (Ethicon): Developing the Ottava robotic surgery platform and a broad laparoscopic instrument portfolio. Overlaps with Livsmed's ArtiSential handheld devices and STARK robotic system across hospitals.
  • CMR Surgical: Maker of the Versius surgical robot, a modular, small-footprint robotic system competing in laparoscopic procedures. Most directly comparable to STARK on cost/accessibility positioning outside the US.

Emerging players

  • Moon Surgical: Early-stage surgical robotics company developing a smaller-footprint robotic-assisted laparoscopic platform (Maestro). Competes on the same cost-and-footprint value proposition as STARK.
  • Vicarious Surgical: Develops a single-port robotic surgical system with virtual reality and decoupled actuator architecture. Targets abdominal minimally invasive surgery, overlapping with Livsmed's articulating instrument approach.
  • FlexDex Surgical: U.S. surgical instrument specialist whose IP assets (89 items) were acquired by Livsmed. Originally developed articulating needle drivers/instruments in the same multi-joint category as ArtiSential.

Broad incumbents

  • Stryker: Operates the Mako robotic surgery platform (orthopedics) plus a broad surgical instruments and endoscopy portfolio. A broad incumbent with overlapping surgical robotics ambitions.
  • Karl Storz: Global leader in endoscopic and laparoscopic instruments with recent robotics investments (including Asensus Surgical). Directly comparable product portfolio in laparoscopic visualization and instrumentation.
  • Olympus: Major laparoscopic/endoscopic instrument manufacturer with growing surgical robotics exposure. Competes with Livsmed's ArtiSential in articulating laparoscopic instruments and adjacent to STARK.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Livsmed social profiles

Digital presence

Livsmed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Livsmed leadership team

Management profile

Number of profiles

Profiles1 record

Livsmed funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Livsmed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Livsmed

What does Livsmed do?

Livsmed manufactures and sells minimally invasive surgical hardware, including the ArtiSential multi-joint handheld laparoscopic surgical device and the STARK telesurgery-native robotic surgical system. Products are sold to hospitals and healthcare providers for use in laparoscopic and robotic minimally invasive surgical procedures, including long-distance telesurgery applications.

Is Livsmed a public or private company?

Livsmed is a public company. It is classified as public and is currently ipo.

When was Livsmed founded?

Livsmed was founded in 2015. It employs 101 to 250 people.

Where is Livsmed based?

Livsmed is headquartered in San Diego, United States, in the North America region.

How does Livsmed make money?

One revenue line is on record: surgical Instruments and Robotics Hardware.

Who are Livsmed's main competitors?

Direct peers on record are Intuitive Surgical, Medtronic, Johnson & Johnson MedTech (Ethicon) and CMR Surgical. Emerging players are Moon Surgical, Vicarious Surgical and FlexDex Surgical. Broad incumbents are Stryker, Karl Storz and Olympus.

Does Livsmed have an API?

No public API is recorded for Livsmed.

What industry is Livsmed in?

Livsmed's product category is Surgical Robotics and Minimally Invasive Surgical Devices. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLivsmed to present at Korea Premium Weeks investor conferenceLivsmed will attend the Korea Premium Weeks 2026 investor relations event on Oct. 7, 2026, in Seoul. The session is scheduled for 13:30-17:00 local time at the Korea Exchange PR Hall, where management will present business updates and take investor questions.뉴스톱리브스메드, 차세대 수술 로봇 'STARK' 글로벌 첫 공개 - 뉴스톱Livosmed unveiled its next-generation surgical robot STARK on the 26th at Seoul's Grand Intercontinental Parinas Hotel, with over 120 surgeons attending. The robot features 90-degree articulation and a slim design, aiming to lower costs and expand access. Livosmed targets domestic certification by 2026, then Japan and the US.뉴스톱리브스메드 아티센셜, 로봇수술 대체 가능성 세계 첫 입증 - 뉴스톱Livsmed's Arthos, a multi-articulated laparoscopic instrument, was shown to match robotic surgery in rectal cancer treatment in a 740-patient multicenter study published in IJS. The procedure cost patients about 3.3 million won, one-fifth of robotic surgery, and took 126 minutes versus 153. The company plans to unveil its next-generation robotic system, Starck.뉴스톱리브스메드, '다관절 원천기술'로 완성한 전 제품 로드맵 첫 공개 - 뉴스톱Livsmed unveiled its product roadmap at KSERS 2026, starting with the multi-articulation laparoscopic instrument ArtiSential and including ArtiSeal, ArtiStapler, LivsCam, and the surgical robot STARK. The roadmap is built on Livsmed's proprietary multi-articulation technology, with STARK's unveiling scheduled for May 26.뉴스톱리브스메드, 초정밀 영상 아키텍처 기업 LAD와 전략적 투자 계약체결 - 뉴스톱Livsmed signed a strategic investment and partnership contract with Japanese imaging firm LAD on the 21st. The deal aims to secure next-generation surgical imaging technology and joint R&D, with LAD's real-time brightness optimization addressing laparoscopic vision limits. Livsmed plans to complete regulatory approvals this year.openPR.comIn-Depth Examination of Segments, Industry Developments, and Key Competitors in the Laparoscopic Instruments MarketThe laparoscopic instruments market is projected to reach $22.47 billion by 2030, growing at a CAGR of 8.8%, driven by advancements in robotic-assisted surgeries and increasing preference for minimally invasive procedures. In March 2025, US-based Lohmann & Rauscher Group acquired UK company Unisurge International Ltd. to strengthen its product portfolio in laparoscopic instruments for hospital and operating room segments. In October 2024, LivsMed Inc. launched the ArtiSential 5, the first 5 mm wristed articulating laparoscopic instrument series, offering enhanced flexibility and reduced recovery times.ChosunbizStonebridge sells 1% Livsmed stake via block deal, recoups 14.7 billion wonStonebridge Ventures sold approximately 1% of its Livsmed equity (264,690 shares) through a block deal at 55,460 won per share, recouping 14.7 billion won. The VC firm, which held 12.72% equity as of Livsmed's KOSDAQ listing on December 24 last year, began recoupment about a week after the listing and plans to use block deals to long-only funds for continued equity sales while stabilizing the stock price. Livsmed develops surgical instruments including the 'ArtiSential' laparoscopic surgical device.TherobotreportLivsMed completes Korean IPO to accelerate remote robotic surgeryLivsMed LLC completed an IPO on Korea's KOSDAQ market, raising approximately $94 million at ₩55,000 per share and achieving unicorn status with a market capitalization of roughly $1 billion. The company plans to use the proceeds to build an integrated production base, fund R&D, and strengthen management systems to support global growth across its surgical robotics and minimally invasive instrument portfolio. LivsMed also demonstrated its STARK surgical robot in a telesurgery feasibility study conducted with Sovato, with the surgeon console in California and the robotic system in Chicago, and draws investment from major domestic pension funds, institutions, and global financial firms.ChosunbizLivsmed acquires FlexDex assets to fortify multi-joint surgical instrument leadLivsmed, a Korean medical device company, acquired technology assets including 89 intellectual property rights (63 patents, 17 trademarks, 9 designs) from U.S. surgical instrument specialist FlexDex Surgical, expanding its total IP portfolio to 939 items. The acquisition is viewed as a blocking patent strategy that covers the entire multi-joint, multi-degrees-of-freedom surgical instrument platform, creating competitive barriers for rivals. Livsmed plans to launch its surgical robot Stark within the year, expanding from handheld laparoscopic instruments into robotic surgery.ChosunbizLivsmed jumps over 10% in KOSDAQ debutLivsmed, a South Korean surgical instrument specialist, debuted on the KOSDAQ market on the 24th with its stock rising more than 10% from the offering price of 55,000 won, trading at 60,900 won by mid-morning. The company, which commercialized the world's first 90-degree multi-joint handheld surgical instrument for laparoscopic surgery, attracted strong investor demand with a 231-to-1 competition rate in institutional book-building and a 390-to-1 rate in retail subscriptions, collecting 6.6363 trillion won in subscription margin. Livsmed plans to use the IPO proceeds to build an integrated production base, fund research and development, and improve related management systems.